Guo Taowen, Zhang Xiaobo, Hu Yicun, Lin Maoqiang, Zhang Ruihao, Chen Xiangyi, Yu Dechen, Yao Xin, Wang Peng, Zhou Haiyu
Department of Orthopedics, Lanzhou University Second Hospital, Lanzhou, China.
Key Laboratory of Bone and Joint Disease Research of Gansu Province, Lanzhou, China.
Front Bioeng Biotechnol. 2022 Jul 19;10:933901. doi: 10.3389/fbioe.2022.933901. eCollection 2022.
Intervertebral disc (IVD) degeneration (IVDD) has been considered the dominant factor in low back pain (LBP), and its etiological mechanisms are complex and not yet fully elucidated. To date, the treatment of IVDD has mainly focused on relieving clinical symptoms and cannot fundamentally solve the problem. Recently, a novel microsphere-based therapeutic strategy has held promise for IVD regeneration and has yielded encouraging results with experiments and animal models. With excellent injectability, biocompatibility, and biodegradability, this microsphere carrier allows for targeted delivery and controlled release of drugs, gene regulatory sequences, and other bioactive substances and supports cell implantation and directed differentiation, aiming to improve the disease state of IVD at the source. This review discusses the possible mechanisms of IVDD and the limitations of current therapies, focusing on the application of microsphere delivery systems in IVDD, including targeted delivery of active substances and drugs, cellular therapy, and gene therapy, and attempts to provide a new understanding for the treatment of IVDD.
椎间盘退变(IVDD)被认为是腰痛(LBP)的主要因素,其发病机制复杂,尚未完全阐明。迄今为止,IVDD的治疗主要集中在缓解临床症状,无法从根本上解决问题。最近,一种基于微球的新型治疗策略为椎间盘再生带来了希望,并在实验和动物模型中取得了令人鼓舞的结果。这种微球载体具有出色的可注射性、生物相容性和生物降解性,能够实现药物、基因调控序列和其他生物活性物质的靶向递送和控释,并支持细胞植入和定向分化,旨在从源头上改善椎间盘的疾病状态。本文综述了IVDD的可能机制和当前治疗方法的局限性,重点讨论了微球递送系统在IVDD中的应用,包括活性物质和药物的靶向递送、细胞治疗和基因治疗,并试图为IVDD的治疗提供新的认识。